News Sentiment

MPLT sentiment intelligence

MapLight Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 74 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.32 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 66

directly relevant articles

Source quality 7

high-authority source matches

Trend context Trend active

+6.0% over one week, +41.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.0% Price confirming higher
Trend fit Trend active 41.7% over four weeks
Fair value 75.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 48
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 66
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 9
MarketBeat 4
MT Newswires 3
Seeking Alpha 3
simplywall.st 3
Investing.com Canada 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 24
Analyst action 11
Deals and strategy 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 74
grafa.com Direct company coverage

MapLight reports Phase 2 autism trial results for ML-004

MapLight announced that its Phase 2 trial of ML-004 for autism did not meet its primary endpoint, failing to improve caregiver-reported social communication scores in 161 patients. However, a prespecified subgroup analysis of 20 adolescent patients showed a statistically signific

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 11:56
Source
grafa.com
Investing.com Canada Direct company coverage

MapLight’s autism drug trial misses primary endpoint By Investing.com

MapLight Therapeutics announced its Phase 2 IRIS trial for ML-004 in autism spectrum disorder failed to meet its primary endpoint, showing no significant improvement in social communication deficits. Despite the setback, the company's shares have risen significantly year-to-date,

Tone
Negative 35/100
Event
Market update
Published
22 Jun 2026 11:07
Source
Investing.com Canada
Stock Titan Direct company coverage

Strong adolescent irritability signal in MapLight (MPLT) ML-004 Phase 2 IRIS trial

MapLight Therapeutics announced mixed Phase 2 IRIS trial results for ML-004 in autism spectrum disorder. While the study did not meet its primary endpoint for social communication deficits, it showed a robust, clinically meaningful reduction in irritability among adolescents with

Tone
Positive 59/100
Event
Earnings
Published
22 Jun 2026 10:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

MapLight Therapeutics, Inc.(NasdaqGS:MPLT) added to S&P Biotechnology Select Industry Index

MapLight Therapeutics, Inc. (NasdaqGS: MPLT) has been added to the S&P Biotechnology Select Industry Index. This news follows several other recent announcements for the company, including executive appointments, analyst initiations with "Buy" ratings, and insider stock transactio

Tone
Positive 71/100
Event
Analyst action
Published
22 Jun 2026 01:10
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Maplight Therapeutics, Inc. Appoints Jonathan Gillis as Interim Principal Financial Officer, Effective June 18, 2026

MapLight Therapeutics, Inc. has announced the appointment of Jonathan Gillis as its interim principal financial officer, effective June 18, 2026. Gillis, who currently serves as the company's Chief Administrative and Accounting Officer, will also maintain his role as principal ac

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 10:39
Source
www.marketscreener.com
TradingKey Direct company coverage

MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for MapLight Therapeutics Inc (MPLT), highlighting that 11 analysts currently rate the stock as a "Buy" with a target price indicating a 34.28% upside. The report includes key financial metrics like market cap, P/E TTM, and a comparison

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 22:39
Source
TradingKey